Justin Smith
Stock Analyst at Bernstein
(4.20)
# 1,509
Out of 5,010 analysts
157
Total ratings
59.5%
Success rate
9.7%
Average return
Main Sectors:
Stocks Rated by Justin Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 20,200p | 12,428p | +62.54% | 36 | Sep 29, 2026 | |
| SWX: SFZN Siegfried Holding AG | Reiterated: Buy | n/a | $72.45 | - | 1 | Sep 14, 2026 | |
| ETR: MRK Merck KGaA | Reiterated: Hold | €112.00 → €151.00 | €137.40 | +9.90% | 2 | Aug 7, 2026 | |
| EPA: SAN Sanofi | Reiterated: Buy | €107.00 → €106.21 | €71.47 | +48.61% | 4 | Aug 4, 2026 | |
| LON: GSK GSK plc | Reiterated: Buy | 2,825p → 3,010p | 1,856p | +62.18% | 25 | Aug 3, 2026 | |
| SWX: ROP Roche Holding AG | Reiterated: Buy | CHF 395.00 → CHF 434.50 | CHF 349.30 | +24.39% | 26 | Jul 27, 2026 | |
| SWX: LONN Lonza Group AG | Reiterated: Buy | n/a | $584.00 | - | 9 | Jul 24, 2026 | |
| SWX: NOVN Novartis AG | Rated: Hold | CHF 125.00 → CHF 133.00 | CHF 120.92 | +9.99% | 2 | Jul 22, 2026 | |
| NVS Novartis AG | Initiated Coverage: Hold | n/a | $145.71 | - | 1 | Mar 19, 2026 | |
| GMAB Genmab | Reiterated: Sell | n/a | $35.57 | n/a | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $28.72 | n/a | 8 | Aug 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | €10.50 → €2.90 | €0.74 | n/a | 3 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €22.00 → €21.50 | €9.49 | n/a | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $85 → $51 | $62.86 | n/a | 10 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $104 | $149.28 | n/a | 4 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | €45.80 → €71.00 | €39.20 | n/a | 7 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €69.00 → €70.00 | €44.20 | n/a | 6 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $52.23 | n/a | 2 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $172 → $140 | $263.29 | n/a | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $49.35 | n/a | 1 | Sep 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $12.62 | n/a | 1 | Nov 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $22.27 | n/a | 1 | Feb 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $78 | $1,184.63 | n/a | 1 | Apr 7, 2016 |
AstraZeneca PLC
Sep 29, 2026
Reiterated: Buy
Price Target: 20,200p
Current: 12,428p
Upside: +62.54%
Siegfried Holding AG
Sep 14, 2026
Reiterated: Buy
Price Target: n/a
Current: $72.45
Upside: -
Merck KGaA
Aug 7, 2026
Reiterated: Hold
Price Target: €112.00 → €151.00
Current: €137.40
Upside: +9.90%
Sanofi
Aug 4, 2026
Reiterated: Buy
Price Target: €107.00 → €106.21
Current: €71.47
Upside: +48.61%
GSK plc
Aug 3, 2026
Reiterated: Buy
Price Target: 2,825p → 3,010p
Current: 1,856p
Upside: +62.18%
Roche Holding AG
Jul 27, 2026
Reiterated: Buy
Price Target: CHF 395.00 → CHF 434.50
Current: CHF 349.30
Upside: +24.39%
Lonza Group AG
Jul 24, 2026
Reiterated: Buy
Price Target: n/a
Current: $584.00
Upside: -
Novartis AG
Jul 22, 2026
Rated: Hold
Price Target: CHF 125.00 → CHF 133.00
Current: CHF 120.92
Upside: +9.99%
Novartis AG
Mar 19, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $145.71
Upside: -
Genmab
Sep 8, 2025
Reiterated: Sell
Price Target: n/a
Current: $35.57
Upside: n/a
Aug 17, 2025
Reiterated: Hold
Price Target: n/a
Current: $28.72
Upside: n/a
Mar 31, 2025
Downgraded: Hold
Price Target: €10.50 → €2.90
Current: €0.74
Upside: n/a
Dec 10, 2024
Reiterated: Buy
Price Target: €22.00 → €21.50
Current: €9.49
Upside: n/a
Mar 11, 2024
Downgraded: Hold
Price Target: $85 → $51
Current: $62.86
Upside: n/a
Mar 11, 2024
Downgraded: Sell
Price Target: $104
Current: $149.28
Upside: n/a
Nov 17, 2023
Upgraded: Buy
Price Target: €45.80 → €71.00
Current: €39.20
Upside: n/a
Nov 17, 2023
Reiterated: Buy
Price Target: €69.00 → €70.00
Current: €44.20
Upside: n/a
Feb 27, 2023
Upgraded: Buy
Price Target: n/a
Current: $52.23
Upside: n/a
Nov 8, 2022
Downgraded: Hold
Price Target: $172 → $140
Current: $263.29
Upside: n/a
Sep 3, 2019
Upgraded: Buy
Price Target: n/a
Current: $49.35
Upside: n/a
Nov 12, 2018
Reiterated: Buy
Price Target: n/a
Current: $12.62
Upside: n/a
Feb 24, 2017
Downgraded: Hold
Price Target: n/a
Current: $22.27
Upside: n/a
Apr 7, 2016
Initiated Coverage: Hold
Price Target: $78
Current: $1,184.63
Upside: n/a